Ó³»­´«Ã½

Niall Lennon is the senior director of the genomics platform at the Ó³»­´«Ã½ of MIT and Harvard, where he is also an institute scientist. He is also the chief scientific officer and chair of the board of , a wholly owned subsidiary of the institute, and an associate director of the Gerstner Center for Cancer Diagnostics. He oversees the development, implementation, validation, and operation of disruptive technologies and analytical methods to serve research, clinical research, and clinical diagnostics across a range of fields from infectious disease and cancer to rare and chronic diseases.

Lennon has been with the Ó³»­´«Ã½ since 2005, and has contributed to the development of applications for every major genomics technology. He also built a CLIA/CAP licensed clinical laboratory at the Ó³»­´«Ã½ (now known as Ó³»­´«Ã½ Clinical Labs) to facilitate return of results to patients and to support clinical trials. More recently, Lennon has led efforts to achieve FDA approval for both large-scale genomics projects (NIH’s All of Us Research Program) and for Ó³»­´«Ã½â€™s own clinical diagnostic for COVID-19 testing process that delivered more than 37M diagnostic test results to people in the New England region.

He received a Ph.D. in pharmacology from University College Dublin and completed his postdoctoral studies at Harvard Medical School and Massachusetts General Hospital. He holds an executive certificate in management from the MIT Sloan School of Management.